Common Red Flags in Site Capability Assessments for Clinical Trials

Introduction: Recognizing Risk Early in Site Feasibility

Clinical trial success depends heavily on selecting qualified, reliable, and compliant investigator sites. The feasibility and site capability assessment process is designed to evaluate a site’s readiness before study activation. However, sponsors and CROs must go beyond standard questionnaires and proactively identify red flags that signal potential risk. These indicators—whether related to infrastructure, staffing, past performance, or regulatory behavior—can help prevent costly protocol deviations, enrollment failures, or inspection findings later in the trial.

This article outlines the most common red flags encountered during capability assessments, providing sponsors and feasibility managers with a practical reference to enhance site selection rigor. It also discusses methods to mitigate or validate questionable areas before making final site activation decisions.

1. Incomplete or Vague Questionnaire Responses

A feasibility questionnaire is a foundational tool for initial site screening. However, when responses are incomplete, vague, or inconsistent, it often signals deeper issues:

• Key questions left blank (e.g., previous trial experience, equipment availability)
• Generic answers like “Will arrange” or “To be confirmed”
• Discrepancies between answers and historical performance data
• Overestimated enrollment figures without justification

Feasibility reviewers should flag such responses for immediate clarification or request supporting documentation such as patient logs, SOP samples, or CVs.

2. Lack of Therapeutic Area Experience

Site experience in the relevant therapeutic area is one of the most critical success factors. Red flags include:

• Principal Investigator (PI) has no previous experience with similar trials
• Sub-investigators or site staff are generalists without therapeutic alignment
• No access to relevant patient population or specialist support services

Example: A site applying for a Phase II oncology study has only conducted dermatology trials, with no history of chemotherapy handling or tumor assessment procedures. Despite availability of infrastructure, lack of therapeutic alignment increases protocol deviation and data quality risks.

3. Overcommitted or Inaccessible PI

The availability and oversight role of the Principal Investigator are mandated under ICH GCP. Red flags include:

• PI managing more than five active studies simultaneously
• PI unavailable for feasibility or pre-study visit interviews
• Delegation of Duties Log shows heavy reliance on study coordinator
• PI does not personally sign or review the feasibility forms

Such scenarios raise serious concerns about supervision quality and data integrity. Sponsors should confirm the PI’s commitment level and availability during key protocol visits.

4. Inadequate Infrastructure or Missing Equipment

Basic infrastructure gaps should immediately raise concern:

• Absence of a -20°C or -80°C freezer for sample storage
• No secure IP storage area or temperature monitoring
• Uncalibrated ECG machines or centrifuges
• Shared clinical space with no patient privacy

Site walkthroughs, photo documentation, and equipment calibration certificates should be reviewed to confirm adequacy. Sites missing essential tools may require investment, training, or conditional approval with time-bound CAPAs.

5. Outdated or Missing SOPs

Standard Operating Procedures are essential for repeatable, compliant trial conduct. SOP-related red flags include:

• SOPs older than 2 years with no revision history
• Missing SOPs for key areas: IP management, AE/SAE reporting, consent
• Staff unaware of SOP contents or unable to retrieve documents
• No SOP training records or signature logs

Feasibility assessors should request a full SOP index and spot-check 3–5 SOPs for content, signatures, and alignment with protocol needs.

6. History of Protocol Deviations or Audit Findings

Past performance is a strong predictor of future behavior. Red flags in this area include:

• Multiple protocol deviations reported in recent trials
• High rate of screen failures or patient withdrawals
• Findings from sponsor QA audits or regulatory inspections (e.g., Form FDA 483)
• Unresolved CAPAs or lack of documented root cause analysis

Site performance should be verified against internal CTMS or monitoring reports. Sites with unresolved issues may require escalated review or rejection from selection.

7. Missing or Delayed Documentation

A site’s responsiveness and attention to documentation directly correlate with their operational readiness. Red flags include:

• Delays in submitting CVs, training certificates, or questionnaires
• Unsigned or incomplete delegation logs
• Conflicting names or data across feasibility and regulatory documents
• Electronic signatures not compliant with 21 CFR Part 11 or Annex 11

Timely documentation is a baseline expectation. Sites unable to provide critical files during feasibility may struggle with startup and regulatory inspection preparedness.

8. High Staff Turnover or Understaffing

Staffing instability affects trial continuity and protocol compliance. Feasibility reviewers should flag:

• New or untrained study coordinators without trial experience
• Single-person clinical teams with no backup for key functions
• Recent turnover of PI or sub-investigators within 3 months
• No defined roles and responsibilities in site organizational chart

Sponsors may request staffing plans, interview the full study team, and assess their capacity for protocol-required tasks.

9. Resistance to Remote Monitoring or Digital Tools

Modern trials increasingly require eCRF, remote SDV, eConsent, and EDC/IRT access. Sites presenting digital reluctance or technical limitations pose risks:

• No access to validated computers or secure internet
• Limited experience with EDC platforms like RAVE or InForm
• Inability to support remote access for monitors
• Refusal to implement eConsent or telemedicine components

Technology readiness should be included in the feasibility checklist, and weak areas flagged for additional IT onboarding or support requirements.

10. Ethics Committee Delays or Regulatory Barriers

Sites with historically long or unpredictable EC/IRB timelines can delay study startup. Other red flags include:

• Unregistered EC or expired accreditation
• EC meets infrequently or lacks electronic submission
• Complex internal hospital approval layers beyond IRB
• Frequent protocol rejections or consent template rework

Sites should be asked to provide average EC timelines and prior approval letters to validate claims of startup readiness.

Addressing Red Flags: Not All Are Disqualifiers

While red flags help identify high-risk sites, they do not always require disqualification. Sponsors may take one of several approaches:

• Request clarification or additional documents before final decision
• Implement conditional approval with time-bound CAPAs
• Schedule a follow-up visit or teleconference with PI
• Provide protocol-specific training or infrastructure support

Documentation of risk mitigation measures should be recorded in the site qualification file and Trial Master File (TMF).

Best Practices for Red Flag Identification

• Use standardized feasibility scoring tools with risk weightings
• Document all observations during pre-study visits and interviews
• Cross-check responses with internal CTMS, audit logs, and inspection histories
• Maintain a red flag log for all candidate sites with reviewer comments
• Engage QA or clinical operations leads in risk-based site selection meetings

Conclusion

Identifying red flags during site capability assessments is essential to conducting risk-based site selection in clinical trials. By recognizing common indicators—ranging from missing documentation to infrastructure gaps or performance history concerns—sponsors can proactively avoid delays, compliance failures, and quality issues. Red flag management should be systematic, documented, and integrated into the sponsor’s feasibility SOPs and TMF documentation processes. Through early detection and structured mitigation, sponsors improve trial reliability, inspection readiness, and operational efficiency across the study lifecycle.